Data sources and methods for ascertaining human exposure to drugs.

Area of Science:

• Pharmacovigilance
• Epidemiology
• Public Health

Background:

• Population drug exposure estimates are crucial for post-marketing surveillance.
• This data informs risk-benefit assessments, morbidity prediction, and public health strategies.
• Understanding exposure scales influences regulatory actions and study design (e.g., case-control, cohort).

Purpose of the Study:

• To evaluate the utility and limitations of national drug use databases for post-marketing surveillance.
• To identify gaps in current data collection methods for drug exposure.
• To assess the suitability of existing databases for epidemiological research.

Main Methods:

• Analysis of existing national drug use databases accessible to the FDA.
• Identification of data limitations including lack of OTC drug use accuracy, hospital use qualitative data, and patient linkage.
• Examination of database methodologies, sampling frames, and projection techniques.

Main Results:

• National drug use databases provide an overview of common therapies and comparison data.
• Significant limitations exist, including inability to accurately measure over-the-counter (OTC) drug use and lack of qualitative hospital data.
• Databases lack patient linkage, preventing longitudinal use analysis and direct connections between different data sources.
• Methodology changes by market research companies pose challenges for consistent epidemiological research.
• Subscription-based nature of databases imposes contractual obligations and review processes for data release.

Conclusions:

• Despite limitations, national drug use databases offer advantages for understanding drug use trends.
• Addressing data gaps in OTC and hospital drug use, and improving patient linkage, is essential.
• Standardization and transparency in database methodologies are needed for robust epidemiological research.